Columbus Circle Investors buys $250,505,762 stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Columbus Circle Investors scooped up 33,790 additional shares in Edwards Lifesciences Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 2,209,825 shares of Edwards Lifesciences Corp which is valued at $250,505,762.Edwards Lifesciences Corp makes up approximately 2.40% of Columbus Circle Investors’s portfolio.

Other Hedge Funds, Including , Public Employees Retirement Association Of Colorado reduced its stake in EW by selling 1,455 shares or 3.03% in the most recent quarter. The Hedge Fund company now holds 46,613 shares of EW which is valued at $5,338,121. Edwards Lifesciences Corp makes up approx 0.04% of Public Employees Retirement Association Of Colorado’s portfolio.Conning boosted its stake in EW in the latest quarter, The investment management firm added 10 additional shares and now holds a total of 5,256 shares of Edwards Lifesciences Corp which is valued at $601,497. Edwards Lifesciences Corp makes up approx 0.02% of Conning’s portfolio.Fox Run Management L.l.c. reduced its stake in EW by selling 400 shares or 5.71% in the most recent quarter. The Hedge Fund company now holds 6,600 shares of EW which is valued at $704,286. Edwards Lifesciences Corp makes up approx 0.33% of Fox Run Management L.l.c.’s portfolio.

Edwards Lifesciences Corp closed down -0.83 points or -0.73% at $112.4 with 7,70,687 shares getting traded on Monday. Post opening the session at $113.37, the shares hit an intraday low of $112 and an intraday high of $113.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *